Also, CFO Robert E. Landry sold 739 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, February 3rd.

Source: https://www.etfdailynews.com/2023/04/08/park-avenue-securities-llc-buys-64-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn/

BMO Capital Markets lifted their target price on Regeneron Pharmaceuticals from $1,001.00 to $1,025.00 and gave the company an outperform rating in a research report on Tuesday, March 14th.

Source: https://www.dailypolitical.com/2023/03/27/barclays-increases-regeneron-pharmaceuticals-nasdaqregn-price-target-to-915-00.html

Cibc World Market Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 1.4% during the 1st quarter.

Source: https://www.americanbankingnews.com/2023/04/10/ballentine-partners-llc-acquires-194-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html

Dynamic Advisor Solutions LLC’s holdings in Regeneron Pharmaceuticals were worth $299,000 as of its most recent filing with the SEC.

Source: https://www.etfdailynews.com/2023/01/01/dynamic-advisor-solutions-llc-has-299000-stock-holdings-in-regeneron-pharmaceuticals-inc-nasdaqregn/

Eqis Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,160,000 as of its most recent SEC filing.

Source: https://www.etfdailynews.com/2023/12/02/eqis-capital-management-inc-lowers-position-in-regeneron-pharmaceuticals-inc-nasdaqregn/

Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 34.05 earnings per share for the current year.

Source: https://www.etfdailynews.com/2023/04/05/allspring-global-investments-holdings-llc-trims-stock-position-in-regeneron-pharmaceuticals-inc-nasdaqregn/

Finally, Plancorp LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 0.8% during the 1st quarter.

Source: https://www.etfdailynews.com/2023/01/01/dynamic-advisor-solutions-llc-has-299000-stock-holdings-in-regeneron-pharmaceuticals-inc-nasdaqregn/

Finally, Royal Bank of Canada upped their target price on Regeneron Pharmaceuticals from $811.00 to $816.00 in a research report on Friday.

Source: https://www.americanbankingnews.com/2023/06/10/advisors-asset-management-inc-has-6-02-million-stock-position-in-regeneron-pharmaceuticals-inc-nasdaqregn.html

Finally, SVB Leerink raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, March 27th.

Source: https://www.americanbankingnews.com/2023/04/05/greenleaf-trust-has-1-40-million-holdings-in-regeneron-pharmaceuticals-inc-nasdaqregn.html

Finally, Truist Financial reaffirmed a “buy” rating and set a $1,045.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 16th.

Source: https://www.americanbankingnews.com/2023/11/05/regeneron-pharmaceuticals-nasdaqregn-pt-lowered-to-837-00.html

For its part, Regeneron says it plans to work with the FDA to address its concerns.

Source: https://investorplace.com/2023/08/biotech-stocks-to-buy-3/

Great Lakes Advisors LLC purchased a new position in Regeneron Pharmaceuticals, Inc. () in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC).

Source: https://www.etfdailynews.com/2023/08/21/1789-shares-in-regeneron-pharmaceuticals-inc-nasdaqregn-acquired-by-great-lakes-advisors-llc/

In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 739 shares of the company’s stock in a transaction that occurred on Friday, February 3rd.

Source: https://www.etfdailynews.com/2023/04/05/allspring-global-investments-holdings-llc-trims-stock-position-in-regeneron-pharmaceuticals-inc-nasdaqregn/

In other Regeneron Pharmaceuticals news, CFO sold 223 shares of the firm’s stock in a transaction dated Wednesday, August 23rd.

Source: https://www.etfdailynews.com/2023/10/15/regeneron-pharmaceuticals-nasdaqregn-given-new-915-00-price-target-at-morgan-stanley/

Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $897.00 to $912.00 and gave the stock an “overweight” rating in a research note on Friday, August 4th.

Source: https://www.etfdailynews.com/2023/09/10/price-t-rowe-associates-inc-md-raises-stock-position-in-regeneron-pharmaceuticals-inc-nasdaqregn/

Norges Bank bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $697,296,000.

Source: https://www.americanbankingnews.com/2023/08/21/atria-investments-inc-acquires-295-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html

Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $775.00 to $765.00 and set an “overweight” rating for the company in a report on Thursday, November 3rd.

Source: https://www.etfdailynews.com/2023/02/10/equities-analysts-set-expectations-for-regeneron-pharmaceuticals-inc-s-q1-2024-earnings-nasdaqregn/

Regeneron Pharmaceuticals has a 52-week low of $538.01 and a 52-week high of $800.48.

Source: https://www.etfdailynews.com/2023/02/10/equities-analysts-set-expectations-for-regeneron-pharmaceuticals-inc-s-q1-2024-earnings-nasdaqregn/

Regeneron Pharmaceuticals () is a large cap pharmaceutical company best known for its eye disease therapy Eylea.

Source: https://seekingalpha.com/article/4590064-regeneron-pharmaceuticals-boosted-copd-data?source=feed_all_articles

Renaissance Technologies LLC grew its stake in shares of Regeneron Pharmaceuticals by 108.3% in the second quarter.

Source: https://www.americanbankingnews.com/2023/03/04/alphacrest-capital-management-llc-sells-3230-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html